Moderna CEO sets 2027 FDA submission target for personalised cancer vaccine intismeran
Stéphane Bancel has outlined a regulatory timeline and expansion strategy for intismeran following phase 3 melanoma data presented at ESMO 2026.
Moderna CEO Stéphane Bancel has indicated the company intends to submit intismeran — its personalised mRNA neoantigen vaccine developed with Merck — for FDA approval in 2027, following the phase 3 data presented at the European Society for Medical Oncology (ESMO) meeting in Madrid earlier this month. Speaking to STAT News, Bancel outlined plans for the vaccine's commercial and pipeline strategy beyond melanoma.
Intismeran works by generating a bespoke mRNA sequence tailored to the mutational profile of an individual patient's tumour, enabling the immune system to target neoantigens specific to that cancer. The phase 3 KEYNOTE-942 / mRNA-4157-P201 data, reported at ESMO and widely covered in recent days, showed a 42% reduction in melanoma recurrence when intismeran was combined with pembrolizumab (Keytruda).
This item adds business-strategy and regulatory-timeline context to the clinical data already summarised in Genetic Current on 23 October and 25 October 2026. The underlying science of the vaccine and the ESMO data presentation have been covered in previous clusters; the primary new element here is the CEO's stated 2027 submission target and comments on expansion into further tumour types. Readers seeking the clinical trial data should refer to the 23 October cluster.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-26Moderna CEO on what's next after success in cancer vaccine
-
Stat News · 2026-10-26STAT+: Five biotech updates to read after ESMO this weekend
-
Stat News · 2026-10-25STAT+: After a cancer vaccine's first success, the race is on to expand the impact
-
Stat News · 2026-10-24STAT+: The ESMO presentation everyone's been waiting for